Affiliation:
1. Narayana Superspecilty RN Tagore Hospital Howrah, Howrah, West Bengal, India
Abstract
Abstract
Giant cell tumour (GCT) of bone (GCTB) is a type of giant cell-rich bone lesion specified by the presence of numerous multinucleated osteoclast-type giant cells. Giant cells are known to express receptor activator of nuclear factor-kappa B ligand (RANKL) and are responsible for the aggressive osteolytic nature of the tumour. No available treatment option is definitively effective in curing this disease, especially in surgically unsalvageable cases. Denosumab is a fully human monoclonal antibody that targets and binds with high affinity and specificity to RANKL. Results from the studies suggest that denosumab is potentially effective treatment for patients with GCTB of the spine, including the sacrum. This study is a review to highlight role of denosumab in spinal GCT.
Reference21 articles.
1. Identification of markers of possible prognostic value in 57 giant cell tumors of bone;Gamberi;Oncol Rep,2003
2. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone;Rutkowski;Ann Surg Oncol,2015
3. Giant cell tumor of the sacrum and spine: Series of 23 cases and a review of the literature;Martin;Iowa Orthop J,2010
4. Giant cell tumor of bone;Amanatullah;Orthopedics,2014
5. Giant-cell tumor of bone: Analysis of two hundred and eight cases in Chinese patients;Sung;J Bone Joint Surg Am,1982